News Release

January 11, 2006

Contact: Kristina Goodnough, 860-679-3700

Implant Procedure Available for Treatment-Resistant Depression

UConn Health Center Offers Vagus Nerve Stimulation Therapy

FARMINGTON, CONN. – The Health Center is offering vagus nerve stimulation (VNS) therapy for serious depression, a new treatment approved by the Food and Drug Administration.

The treatment involves implanting a small generator about the size of a stopwatch just under the skin in the left side of the chest and tunneling thin thread-like electrodes under the collarbone to wrap around the left vagus nerve, which relays signals to a part of the brain related to mood and anxiety. Implantation of the device is done in same-day surgery by an otolaryngologist. Then, after a period of about two weeks, psychiatrists work with the patients to program the device to send intermittent, mild electrical pulses through the vagus nerve to the brain and monitor the response

“It’s a welcome addition to the treatments we have for chronic depression, which is one of the most prevalent and serious illnesses in this country and around the world,” says Leighton Huey, M.D., chairman of the Psychiatry Department and director of the program. Depression is typically treated with a combination of medication and psychotherapy, but not everyone responds well, according to Huey. “About 20 to 25 percent of patients suffering from serious, chronic depression respond incompletely or not at all to conventional treatment. We are making the VNS therapy available to patients who have been treated for major episodes of depression at least four times without success or with only partial success.” For those who respond, the effectiveness of VNS therapy seems to grow over time and improvement seems to be maintained for the long term for some people. Some will have full remission of their symptoms, according to Huey.

The device, which was developed by Cyberonics, Inc. of Houston, was first offered as a treatment for people having seizures that did not respond to usual treatment. It was approved for that use in Europe in 1994 and then in the United States and Canada in 1997. Medical researchers found that the device appeared to improve the mood in patients with epilepsy even when it did not substantially reduce their seizures. It was approved for treatment-resistant depression in Europe and Canada in 2001.

“Our program is the only comprehensive one in the state,” says Huey. “We will be working with physicians around the state to make them aware of this treatment and to help them evaluate their patients who might benefit from it.”

For more information on VNS therapy, contact the Health Center’s Department of Psychiatry at 860-679-4282.

UConn Health includes the schools of medicine and dental medicine, the UConn Medical Group, University Dentists, and John Dempsey Hospital. Home to Bioscience Connecticut, UConn Health pursues a mission of providing outstanding health care education in an environment of exemplary patient care, research and public service. More information about UConn Health is available at

Note: News professionals are invited to visit the UConn Health Today news page ( for regularly updated news and feature stories, photos and media stories. News releases are archived at UConn Health news and information is also available on Facebook, Twitter and YouTube.